Please ensure Javascript is enabled for purposes of website accessibility

Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle

By Cory Renauer – Jun 15, 2020 at 10:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's second-generation integrated continuous glucose monitoring system, the Freestyle Libre 2, earned regulatory in Europe over two years ago.

The most popular constant glucose monitor in America is getting a long-awaited upgrade. The FDA has finally cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system from Abbott (ABT 2.85%) for type 1 diabetes patients 4 and older.

It has been more than two years since the next-generation iCGM earned CE Mark clearance in Europe, but Abbott's experience with U.S. regulators wasn't nearly as smooth. The FreeStyle Libre 2 adds Bluetooth capability; the Libre 1 model could only transmit information about a patient's blood sugar levels wirelessly using NFC (near-field communication) protocols.

FDA approved stamp

Image source: Getty Images.

Over the past couple of years, another iCGM, the G6 from Dexcom (DXCM 5.51%), has gained significant popularity, partly because its Bluetooth functionality makes it easier for patients (and their caregivers) to receive alerts on their smartphones the moment their blood sugar reaches a dangerous level.

Why diabetes patients may favor the Freestyle Libre 2

Insurers and government payers have quickly learned that replacing frequent finger-pokes with disposable, stick-on glucose monitors improves diabetes patients' outcomes and reduces their hospitalizations. During the first three months of 2020, worldwide Libre sales rose 59.3% year over year to more than $600 million, which works out to around 20% of Abbott's total revenue at the moment.

Despite the fact that the Libre 1 was less able to interact with popular mobile devices, Abbott hasn't had any trouble holding onto a large share of the U.S. iCGM market with its low-priced device. And given that the Libre 2's sensor has been approved to remain applied to patients for 14 days at a time, its new iCGM could have a leg up on Dexcom's G6 and its 10-day sensor. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$99.52 (2.85%) $2.76
DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$84.98 (5.51%) $4.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.